Company-wide revenue
Reported revenue in 2021 ¥703.3B Reported revenue in 2025 ¥1.13T
- growth amount
- +¥428.57B
- growth annualized
- +12.6%
- growth total
- +60.9%
Japanese company profile · 4543
Terumo Corporation
In its FY2025 public filing, Terumo Corporation reports Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, Terumo Organ Technologies. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: テルモ株式会社
English company name from the issuer's official source. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
Terumo Corporation's largest reported business by revenue in FY2025 was Cardiac and Vascular Company.
The business with the highest reported segment profit in FY2025 was Cardiac and Vascular Company.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Revenue from external customers | Revenue share | Segment profit (loss) |
|---|---|---|---|
| Cardiac and Vascular Company | ¥676.42B ↗ | 59.8% | ¥163.99B ↗ |
| Blood and Cell Technologies Company | ¥231.04B ↗ | 20.4% | ¥33.63B ↗ |
| Medical Care Solutions Company | ¥216.14B ↗ | 19.1% | ¥21.57B ↗ |
| Terumo Organ Technologies | ¥7.99B ↗ | 0.7% | ¥1.67B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Cardiac and Vascular Company
- 心臓血管カンパニー
- Medical Care Solutions Company
- メディカルケアソリューションズカンパニー
- Blood and Cell Technologies Company
- 血液・細胞テクノロジーカンパニー
- Terumo Organ Technologies
- オーガンテクノロジーズ事業
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Original Japanese label
- Cardiac and Vascular Company
- 心臓血管カンパニー
- Medical Care Solutions Company
- メディカルケアソリューションズカンパニー
- Blood and Cell Technologies Company
- 血液・細胞テクノロジーカンパニー
- Terumo Organ Technologies
- オーガンテクノロジーズ事業
- Revenue from external customers
- 外部顧客売上
- Segment profit (loss)
- セグメント利益（損失）
Reported Revenue from external customers by business over time
Reported Revenue from external customers by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cardiac and Vascular Company | ¥397.13B | ¥480.61B | ¥555.72B | ¥624.36B | ¥676.42B |
| Medical Care Solutions Company | ¥185.34B | ¥191.75B | ¥197.57B | ¥211.24B | ¥216.14B |
| Blood and Cell Technologies Company | ¥120.59B | ¥147.6B | ¥168.33B | ¥200.28B | ¥231.04B |
| Terumo Organ Technologies | — | — | — | — | ¥7.99B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Cardiac and Vascular Company
Reported revenue in 2021 ¥397.13B Reported revenue in 2025 ¥676.42B
- growth amount
- +¥279.29B
- growth annualized
- +14.2%
- growth total
- +70.3%
View original filing
Blood and Cell Technologies Company
Reported revenue in 2021 ¥120.59B Reported revenue in 2025 ¥231.04B
- growth amount
- +¥110.45B
- growth annualized
- +17.7%
- growth total
- +91.6%
View original filing
Medical Care Solutions Company
Reported revenue in 2021 ¥185.34B Reported revenue in 2025 ¥216.14B
- growth amount
- +¥30.8B
- growth annualized
- +3.9%
- growth total
- +16.6%
View original filing
Blood and Cell Technologies Company
Reported profit margin in 2022 +7.6%
Reported profit margin in 2025 +14.6%
- growth margin points
- +7.0
View original filing
Medical Care Solutions Company
Reported profit margin in 2022 +7.7%
Reported profit margin in 2025 +10.0%
- growth margin points
- +2.2
View original filing
Cardiac and Vascular Company
Reported profit margin in 2022 +23.3%
Reported profit margin in 2025 +24.2%
- growth margin points
- +0.9
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YGMG
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.